309 related articles for article (PubMed ID: 16988273)
1. A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.
Dunachie SJ; Walther M; Epstein JE; Keating S; Berthoud T; Andrews L; Andersen RF; Bejon P; Goonetilleke N; Poulton I; Webster DP; Butcher G; Watkins K; Sinden RE; Levine GL; Richie TL; Schneider J; Kaslow D; Gilbert SC; Carucci DJ; Hill AV
Infect Immun; 2006 Oct; 74(10):5933-42. PubMed ID: 16988273
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals.
Hodgson SH; Ewer KJ; Bliss CM; Edwards NJ; Rampling T; Anagnostou NA; de Barra E; Havelock T; Bowyer G; Poulton ID; de Cassan S; Longley R; Illingworth JJ; Douglas AD; Mange PB; Collins KA; Roberts R; Gerry S; Berrie E; Moyle S; Colloca S; Cortese R; Sinden RE; Gilbert SC; Bejon P; Lawrie AM; Nicosia A; Faust SN; Hill AV
J Infect Dis; 2015 Apr; 211(7):1076-86. PubMed ID: 25336730
[TBL] [Abstract][Full Text] [Related]
3. Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.
Mensah VA; Gueye A; Ndiaye M; Edwards NJ; Wright D; Anagnostou NA; Syll M; Ndaw A; Abiola A; Bliss C; Gomis JF; Petersen I; Ogwang C; Dieye T; Viebig NK; Lawrie AM; Roberts R; Nicosia A; Faye B; Gaye O; Leroy O; Imoukhuede EB; Ewer KJ; Bejon P; Hill AV; Cisse B;
PLoS One; 2016; 11(12):e0167951. PubMed ID: 27978537
[TBL] [Abstract][Full Text] [Related]
4. A three-antigen Plasmodium falciparum DNA prime-Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults.
Sklar MJ; Maiolatesi S; Patterson N; Sedegah M; Limbach K; Teneza-Mora N; Chuang I; Hollis-Perry KM; Banania JG; Guzman I; Ganeshan H; Reyes S; Hollingdale MR; Wong M; Lindstrom A; Reyes A; Alcorta Y; Garver L; Bankard K; Belmonte A; Belmonte M; Huang J; Gowda K; Inoue S; Velasco R; Bergmann-Leitner E; Hutter J; Lee T; Adams N; Chaudhury S; Hunt D; Tamminga C; Berrie E; Bellamy D; Bittaye M; Ewer K; Diggs C; Soisson LA; Lawrie A; Hill A; Richie TL; Villasante E; Epstein JE; Duplessis CA
PLoS One; 2021; 16(9):e0256980. PubMed ID: 34495988
[TBL] [Abstract][Full Text] [Related]
5. A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults.
Moorthy VS; Imoukhuede EB; Milligan P; Bojang K; Keating S; Kaye P; Pinder M; Gilbert SC; Walraven G; Greenwood BM; Hill AS
PLoS Med; 2004 Nov; 1(2):e33. PubMed ID: 15526058
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.
Moorthy VS; Imoukhuede EB; Keating S; Pinder M; Webster D; Skinner MA; Gilbert SC; Walraven G; Hill AV
J Infect Dis; 2004 Jun; 189(12):2213-9. PubMed ID: 15181568
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
Ogwang C; Afolabi M; Kimani D; Jagne YJ; Sheehy SH; Bliss CM; Duncan CJ; Collins KA; Garcia Knight MA; Kimani E; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Spencer AJ; Soipei P; Mueller J; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Gantlett K; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Urban BC; Flanagan KL; Ewer KJ; Chilengi R; Hill AV; Bojang K
PLoS One; 2013; 8(3):e57726. PubMed ID: 23526949
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™.
Venkatraman N; Anagnostou N; Bliss C; Bowyer G; Wright D; Lövgren-Bengtsson K; Roberts R; Poulton I; Lawrie A; Ewer K; V S Hill A
Vaccine; 2017 Oct; 35(45):6208-6217. PubMed ID: 28941620
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
Moorthy VS; Pinder M; Reece WH; Watkins K; Atabani S; Hannan C; Bojang K; McAdam KP; Schneider J; Gilbert S; Hill AV
J Infect Dis; 2003 Oct; 188(8):1239-44. PubMed ID: 14551895
[TBL] [Abstract][Full Text] [Related]
10. A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees.
Schneider J; Langermans JA; Gilbert SC; Blanchard TJ; Twigg S; Naitza S; Hannan CM; Aidoo M; Crisanti A; Robson KJ; Smith GL; Hill AV; Thomas AW
Vaccine; 2001 Sep; 19(32):4595-602. PubMed ID: 11535306
[TBL] [Abstract][Full Text] [Related]
11. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
Chuang I; Sedegah M; Cicatelli S; Spring M; Polhemus M; Tamminga C; Patterson N; Guerrero M; Bennett JW; McGrath S; Ganeshan H; Belmonte M; Farooq F; Abot E; Banania JG; Huang J; Newcomer R; Rein L; Litilit D; Richie NO; Wood C; Murphy J; Sauerwein R; Hermsen CC; McCoy AJ; Kamau E; Cummings J; Komisar J; Sutamihardja A; Shi M; Epstein JE; Maiolatesi S; Tosh D; Limbach K; Angov E; Bergmann-Leitner E; Bruder JT; Doolan DL; King CR; Carucci D; Dutta S; Soisson L; Diggs C; Hollingdale MR; Ockenhouse CF; Richie TL
PLoS One; 2013; 8(2):e55571. PubMed ID: 23457473
[TBL] [Abstract][Full Text] [Related]
12. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
Bliss CM; Bowyer G; Anagnostou NA; Havelock T; Snudden CM; Davies H; de Cassan SC; Grobbelaar A; Lawrie AM; Venkatraman N; Poulton ID; Roberts R; Mange PB; Choudhary P; Faust SN; Colloca S; Gilbert SC; Nicosia A; Hill AVS; Ewer KJ
Sci Rep; 2018 Feb; 8(1):3390. PubMed ID: 29467399
[TBL] [Abstract][Full Text] [Related]
13. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.
Dunachie S; Berthoud T; Hill AV; Fletcher HA
Vaccine; 2015 Sep; 33(40):5321-31. PubMed ID: 26256523
[TBL] [Abstract][Full Text] [Related]
14. Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Kimani D; Jagne YJ; Cox M; Kimani E; Bliss CM; Gitau E; Ogwang C; Afolabi MO; Bowyer G; Collins KA; Edwards N; Hodgson SH; Duncan CJ; Spencer AJ; Knight MG; Drammeh A; Anagnostou NA; Berrie E; Moyle S; Gilbert SC; Soipei P; Okebe J; Colloca S; Cortese R; Viebig NK; Roberts R; Lawrie AM; Nicosia A; Imoukhuede EB; Bejon P; Chilengi R; Bojang K; Flanagan KL; Hill AV; Urban BC; Ewer KJ
Mol Ther; 2014 Nov; 22(11):1992-2003. PubMed ID: 24930599
[TBL] [Abstract][Full Text] [Related]
15. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
McConkey SJ; Reece WH; Moorthy VS; Webster D; Dunachie S; Butcher G; Vuola JM; Blanchard TJ; Gothard P; Watkins K; Hannan CM; Everaere S; Brown K; Kester KE; Cummings J; Williams J; Heppner DG; Pathan A; Flanagan K; Arulanantham N; Roberts MT; Roy M; Smith GL; Schneider J; Peto T; Sinden RE; Gilbert SC; Hill AV
Nat Med; 2003 Jun; 9(6):729-35. PubMed ID: 12766765
[TBL] [Abstract][Full Text] [Related]
16. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP.
Rampling T; Ewer KJ; Bowyer G; Bliss CM; Edwards NJ; Wright D; Payne RO; Venkatraman N; de Barra E; Snudden CM; Poulton ID; de Graaf H; Sukhtankar P; Roberts R; Ivinson K; Weltzin R; Rajkumar BY; Wille-Reece U; Lee CK; Ockenhouse CF; Sinden RE; Gerry S; Lawrie AM; Vekemans J; Morelle D; Lievens M; Ballou RW; Cooke GS; Faust SN; Gilbert S; Hill AV
J Infect Dis; 2016 Sep; 214(5):772-81. PubMed ID: 27307573
[TBL] [Abstract][Full Text] [Related]
17. Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.
Webster DP; Dunachie S; Vuola JM; Berthoud T; Keating S; Laidlaw SM; McConkey SJ; Poulton I; Andrews L; Andersen RF; Bejon P; Butcher G; Sinden R; Skinner MA; Gilbert SC; Hill AV
Proc Natl Acad Sci U S A; 2005 Mar; 102(13):4836-41. PubMed ID: 15781866
[TBL] [Abstract][Full Text] [Related]
18. Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
Walther M; Thompson FM; Dunachie S; Keating S; Todryk S; Berthoud T; Andrews L; Andersen RF; Moore A; Gilbert SC; Poulton I; Dubovsky F; Tierney E; Correa S; Huntcooke A; Butcher G; Williams J; Sinden RE; Hill AV
Infect Immun; 2006 May; 74(5):2706-16. PubMed ID: 16622207
[TBL] [Abstract][Full Text] [Related]
19. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers.
Webster DP; Dunachie S; McConkey S; Poulton I; Moore AC; Walther M; Laidlaw SM; Peto T; Skinner MA; Gilbert SC; Hill AV
Vaccine; 2006 Apr; 24(15):3026-34. PubMed ID: 16488059
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Plasmodium falciparum Preerythrocytic Antigen UIS3 as a Potential Candidate for a Malaria Vaccine.
Longley RJ; Halbroth BR; Salman AM; Ewer KJ; Hodgson SH; Janse CJ; Khan SM; Hill AVS; Spencer AJ
Infect Immun; 2017 Mar; 85(3):. PubMed ID: 28031267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
